Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Glucagon Receptor
    (11)
  • Glucosidase
    (9)
  • Phosphatase
    (5)
  • Dehydrogenase
    (4)
  • GPCR
    (4)
  • IL Receptor
    (4)
  • Lipoxygenase
    (4)
  • AMPK
    (3)
  • Antibacterial
    (3)
  • Others
    (42)
Filter
Search Result
Results for "

type 1 diabetes

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    150
    TargetMol | Inhibitors_Agonists
  • Peptide Products
    31
    TargetMol | Peptide_Products
  • Inhibitory Antibodies
    7
    TargetMol | Inhibitory_Antibodies
  • PROTAC Products
    1
    TargetMol | PROTAC
  • Natural Products
    11
    TargetMol | Natural_Products
  • Recombinant Protein
    21
    TargetMol | Recombinant_Protein
  • Isotope Products
    1
    TargetMol | Isotope_Products
  • Disease Modeling
    1
    TargetMol | Disease_Modeling_Products
Arjunolic acid
TN1403465-00-9
Arjunolic acid has antioxidant, anti-inflammatory, antinociceptive and anticholinesterasic (AChE and BuChE) activities, it may as promising targets for the development of innovative multi-functional medicines for Alzheimer desease treatment.
  • $197
In Stock
Size
QTY
Phanginin A
T730741011528-58-7In house
Phanginin A, a potent and orally active activator of salt-induced kinase 1 (SIK1), effectively inhibits gluconeogenesis, increases the expression of p-SIK1, and decreases the expression of p-CREB. By reducing blood glucose levels and enhancing glucose tolerance and dyslipidemia, Phanginin A holds potential for type 2 diabetes research.
  • $1,400
7-10 days
Size
QTY
(E)-Guggulsterone
T3656339025-24-6
Bile acids are essential for solubilization and transport of dietary lipids, are the major products of cholesterol catabolism, and are physiological ligands for farnesoid X receptor (FXR), a nuclear receptor that regulates genes involved in lipid metabolism.1They are also inherently cytotoxic, as physiological imbalance contributes to increased oxidative stress.2,3Bile acid-controlled signaling pathways are promising novel targets to treat such metabolic diseases as obesity, type II diabetes, hyperlipidemia, and atherosclerosis.Guggulsterone, derived from resin of the guggul tree, is a competitive antagonist of FXR bothin vitroandin vivo.4Thecisstereoisomer of guggulsterone, (E)-guggulsterone, decreases chenodeoxycholic acid (CDCA)-induced FXR activation with an IC50value of 15 μM.5,6By inhibiting CDCA-induced transactivation of FXR, guggulsterone lowers low-density lipoprotein cholesterol and triglyceride levels in rodents fed a high cholesterol diet.4 1.Makishima, M., Okamoto, A.Y., Repa, J.J., et al.Identification of a nuclear receptor for bile acidsScience2841362-1365(1999) 2.Barbier, O., Torra, I.P., Sirvent, A., et al.FXR induces the UGT2B4 enzyme in hepatocytes: A potential mechanism of negative feedback control of FXR activityGastroenterology1241926-1940(2003) 3.Tan, K.P., Yang, M., and Ito, S.Activation of nuclear factor (erythroid-2 like) factor 2 by toxic bile acids provokes adaptive defense responses to enhance cell survival at the emergence of oxidative stressMol. Pharmacol.72(5)1380-1390(2007) 4.Urizar, N.L., Liverman, A.B., Dodds, D.T., et al.A natural product that lowers cholesterol as an anatagonist ligand for FXRScience296(5573)1703-1706(2002) 5.Cui, J., Huang, L., Zhao, A., et al.Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pumpThe Journal of Biological Chemisty278(12)10214-10220(2003) 6.Wu, J., Xia, C., Meier, J., et al.The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptorMolecular Endocrinology16(7)1590-1597(2002)
  • $59
5 days
Size
QTY
Lysophosphatidylcholine 18:2
PC(18:2 0:0), 1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC, 18:2 0:0-PC, 18:2 lyso-PC, 18:2 LysoPC
T3679122252-07-9
Lysophosphatidylcholine 18:2 is a mouse metabolite functionally related to linoleic acid.18:2 LysoPC is a major component of oxidized low-density lipoproteins (LDLs), and low plasma levels of LPC 18:2 have been associated with metabolic disorders such as impaired glucose tolerance, insulin resistance, type 2 diabetes, and coronary artery disease.1-Linoleoyl 1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC is also a substrate for the generation of lysophosphatidic acid (LPA) from Autotaxin (LysoPLD), which plays an important role in cell motility.
  • $423
35 days
Size
QTY
kuwanon G
Moracenin B, Kuwanone G
T3S161275629-19-5
1. Kuwanon G (Moracenin B) as dual inhibitors of PTP1B and α-glucosidase enzymes, as well as insulin sensitizers, it may potentially be utilized as an effective treatment for Type II diabetes mellitus. 2. Kuwanon G has anti-inflammatory activity, it can attenuate atherosclerosis through inhibiting foam cell formation and inflammatory response. 3. Kuwanon G is a potent inhibitor of Mycobacterium tuberculosis protein tyrosine phosphatase B. 4. Kuwanon G shows acetylcholinesterase (AChE) and butyrylcholinesterase(BChE) inhibitory activities, it may be a promising candidate for preventive and therapeutic agents for Alzheimer's disease. 5. Kuwanon G prevents the pathological progression of allergic asthma through the inhibition of lung destruction by inflammation and immune stimulation. 6. Kuwanon G has antibacterial activity against oral pathogens. 7. Kuwanon G is a specific antagonist for the GRP-preferring receptor and can be useful for studying the physiological and pathological role of GRP.
  • $60
In Stock
Size
QTY
Rhapontin
Rhapontigenin glucoside, Rhaponticin, Rhaponiticin, Ponticin
T5S0384155-58-8
1. Rhapontin (Ponticin) can alleviate liver steatosis and improve blood glucose and lipid profiles in KK Ay diabetic mice, indicates that rhaponticin has a noticeable antidiabetic effect and could be potentially used as a new agent to treat type 2 diabetes mellitus and its complications.
  • $35
In Stock
Size
QTY
Masoprocol
meso-Nordihydroguaiaretic acid, meso-NDGA
T6069227686-84-6
Masoprocol (meso-Nordihydroguaiaretic acid) is a potent, orally active lipoxygenase inhibitor that exhibits antihyperglycemic activity, making it potentially valuable for type II diabetes research. In vivo, Masoprocol reduces glucose and hepatic triglyceride concentrations [1] [2] [3].
  • $166
In Stock
Size
QTY
Pinusolide
TL001431685-80-0
Pinusolide is a platelet activating factor ( PAF) antagonist, it may prove of therapeutic value in the treatment of hypotension, it has antileukemic potential, and could be used to treat neurodegenerative diseases. Pinusolide attenuates blockade of insulin signaling by enhancing IRS-1 tyrosine phosphorylation by the activating the AMPK pathway, indicates the targeting of AMPK represents a new therapeutic strategy for hyperglycemia-induced insulin resistance and type 2 diabetes.
  • $698
Backorder
Size
QTY
Kazinol U
TN43831238116-48-7
Kazinol U may have therapeutic value in delaying pancreatic β-cell destruction in type 1 diabetes by blocking the NF-κB pathway in pancreatic β-cells reduces cell damage. Kazinol U shows estrogenic activity with ligand-activity of estrogen receptor, transcriptional activity of estrogen -responsive element-reporter genes, it may have beneficial effects in the treatment of menopausal symptoms.
  • $390
Backorder
Size
QTY
Norlichexanthone
TN467020716-98-7
Norlichexanthone has the potential to treat and or prevent lifestyle-related diseases such as type 2 diabetes, metabolic syndrome, atherosclerosis and cardiovascular disease. Norlichexanthone has antibacterial and antimalarial activity, it has strong activity against Bacillus subtilis with an IC50 range of 1- 5uM, and also has strong inhibitory effect on the growth of methicillin-resistant Staphylococcus aureus with an IC50 of 20.95±1.56 uM.
  • $535
Backorder
Size
QTY
Methyl stearidonate
SFE 19:4,Moroctic Acid methyl ester
TN772973097-00-4
Methyl stearidonate, a secondary metabolite isolated from Padina tenuis, can be used for research on type 2 diabetes [1].
  • Inquiry Price
Inquiry
Size
QTY